166-180 of 360
Joshua Richter, MD
Sagar Lonial, MD, FACP
Noopur Raje, MD
Sagar Lonial, MD, FACP
Sagar Lonial, MD, FACP
Mastering the Sequence: CELMoDs Across Treatment Lines
MinuteCE®Mastering the Sequence: CELMoDs Across Treatment Lines
Sagar Lonial, MD, FACP
Noopur Raje, MD
Safety First: Navigating CELMoD-Associated Toxicities
MinuteCE®Safety First: Navigating CELMoD-Associated Toxicities
Joshua Richter, MD
Noopur Raje, MD
Real-World Ready: Practical Tips for Community Oncologists
MinuteCE®Real-World Ready: Practical Tips for Community Oncologists
Joshua Richter, MD
Sagar Lonial, MD, FACP
- advertisement
Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
MinuteCE®Case Application: Frontline Insights—Tackling Newly Diagnosed Myeloma
Joshua Richter, MD
Noopur Raje, MD
Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
MinuteCE®Case Application: Unlocking Relapsed/Refractory Myeloma With CELMoDs
Joshua Richter, MD
Sagar Lonial, MD, FACP
Next-Generation Innovations: The Future of CELMoDs in Myeloma
MinuteCE®Next-Generation Innovations: The Future of CELMoDs in Myeloma
Noopur Raje, MD
John M. Kirkwood, MD
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Sapna Patel, MD
Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
MinuteCE®Data Driving Recent Guideline Updates in Neoadjuvant Therapy for Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
MinuteCE®Clinical Implications of Neoadjuvant Therapy Guideline Updates in Resectable Melanoma
John M. Kirkwood, MD
Sapna Patel, MD
- advertisement
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage IIB/IIC Melanoma
Paolo A. Ascierto, MD
Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
MinuteCE®Efficacy and Safety Outcomes for Adjuvant Immunotherapy Driving Guideline Recommendations for Stage III/IV Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
MinuteCE®Implementing Guideline-Concordant Care for a Patient With Newly Diagnosed Stage III Melanoma
Paolo A. Ascierto, MD
Hussein Tawbi, MD, PhD
